CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 31 08 2018
accepted: 21 02 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 2 10 2020
Statut: epublish

Résumé

Selection of human induced pluripotent stem cell (hiPSC) lines with high cardiac differentiation potential is important for regenerative therapy and drug screening. We aimed to identify biomarkers for predicting cardiac differentiation potential of hiPSC lines by comparing the gene expression profiles of six undifferentiated hiPSC lines with different cardiac differentiation capabilities. We used three platforms of gene expression analysis, namely, cap analysis of gene expression (CAGE), mRNA array, and microRNA array to efficiently screen biomarkers related to cardiac differentiation of hiPSCs. Statistical analysis revealed candidate biomarker genes with significant correlation between the gene expression levels in the undifferentiated hiPSCs and their cardiac differentiation potential. Of the candidate genes, PF4 was validated as a biomarker expressed in undifferentiated hiPSCs with high potential for cardiac differentiation in 13 additional hiPSC lines. Our observations suggest that PF4 may be a useful biomarker for selecting hiPSC lines appropriate for the generation of cardiomyocytes.

Identifiants

pubmed: 30874579
doi: 10.1038/s41598-019-40915-w
pii: 10.1038/s41598-019-40915-w
pmc: PMC6420577
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0
PF4 protein, human 0
RNA, Messenger 0
Platelet Factor 4 37270-94-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4638

Références

Sci Rep. 2018 Jun 21;8(1):9466
pubmed: 29930254
Cell Stem Cell. 2008 Mar 6;2(3):219-29
pubmed: 18371447
Cell Rep. 2018 Jan 9;22(2):546-556
pubmed: 29320747
Cell Stem Cell. 2016 Sep 1;19(3):341-54
pubmed: 27476965
N Engl J Med. 2014 Jan 30;370(5):433-43
pubmed: 24350901
Nat Commun. 2014 Dec 03;5:5605
pubmed: 25465724
Cell Stem Cell. 2011 Jun 3;8(6):695-706
pubmed: 21624813
J Clin Invest. 2005 Jul;115(7):1724-33
pubmed: 15951838
Sci Rep. 2018 Feb 27;8(1):3726
pubmed: 29487310
J Biosci Bioeng. 2007 May;103(5):389-98
pubmed: 17609152
Development. 2010 Oct;137(20):3351-60
pubmed: 20876656
Sci Transl Med. 2012 Apr 18;4(130):130ra47
pubmed: 22517884
Tissue Eng Part C Methods. 2018 Jan;24(1):56-67
pubmed: 28967302
Sci Rep. 2017 Oct 26;7(1):14160
pubmed: 29074988
Stem Cell Reports. 2016 Mar 8;6(3):312-20
pubmed: 26905198
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Cytokine Growth Factor Rev. 2011 Feb;22(1):1-18
pubmed: 21111666
Cell Stem Cell. 2011 Feb 4;8(2):228-40
pubmed: 21295278
Biochem J. 2011 Jul 15;437(2):345-55
pubmed: 21554246
Stem Cell Reports. 2015 Apr 14;4(4):744-57
pubmed: 25818811
Sci Rep. 2018 Jan 10;8(1):241
pubmed: 29321579
Circ Cardiovasc Genet. 2013 Oct;6(5):462-71
pubmed: 24036272
Cardiovasc Res. 2011 Jun 1;90(3):430-40
pubmed: 21558279
PLoS One. 2018 Oct 4;13(10):e0205022
pubmed: 30286143
Mol Ther. 2018 Nov 7;26(11):2681-2695
pubmed: 30217728
Cell Stem Cell. 2015 Jun 4;16(6):699-711
pubmed: 26004781
Proc Natl Acad Sci U S A. 2015 May 26;112(21):E2785-94
pubmed: 25964336
Cell Rep. 2017 Apr 4;19(1):20-35
pubmed: 28380358
Nature. 2009 Jan 22;457(7228):413-20
pubmed: 19158787
Circ J. 2004 Jul;68(7):691-702
pubmed: 15226637
Stem Cells. 2014 Sep;32(9):2350-9
pubmed: 24802033
Biochem Biophys Res Commun. 2012 Aug 24;425(2):321-7
pubmed: 22842572
JCI Insight. 2016 Jun 2;1(8):
pubmed: 27398408
J Am Coll Cardiol. 2014 Aug 5;64(5):436-48
pubmed: 25082575
Blood. 2007 Mar 1;109(5):2089-99
pubmed: 17077331
Methods Mol Biol. 2014;1164:67-85
pubmed: 24927836
Circulation. 2013 Apr 23;127(16):1677-91
pubmed: 23519760
Stem Cells. 2008 Sep;26(9):2300-10
pubmed: 18583540
Transplantation. 2019 Feb;103(2):291-298
pubmed: 30119058
Cell Stem Cell. 2015 Jul 2;17(1):89-100
pubmed: 26095046
Development. 2010 Mar;137(6):881-90
pubmed: 20179094
Cell. 2011 Feb 4;144(3):439-52
pubmed: 21295703
Sci Rep. 2017 Aug 15;7(1):8163
pubmed: 28811571
Nature. 2011 Mar 3;471(7336):68-73
pubmed: 21289626
Cell Metab. 2013 Feb 5;17(2):249-60
pubmed: 23395171
Stem Cell Reports. 2013 Jun 04;1(1):46-52
pubmed: 24052941
Cell Rep. 2012 Nov 29;2(5):1448-60
pubmed: 23103164
PLoS One. 2012;7(10):e48659
pubmed: 23119085
PLoS One. 2012;7(5):e37342
pubmed: 22615985
Sci Rep. 2016 Feb 18;6:21747
pubmed: 26888607
J Biol Chem. 2017 Mar 10;292(10):4054-4063
pubmed: 28115521
Sci Rep. 2016 Jan 14;6:19464
pubmed: 26763872
Tissue Eng Part A. 2018 Feb;24(3-4):287-300
pubmed: 28498040
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20569-74
pubmed: 24259714
Nat Biotechnol. 2008 Mar;26(3):313-5
pubmed: 18278034
Stem Cells. 2012 Jun;30(6):1196-205
pubmed: 22438013
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15776-81
pubmed: 14663149
PLoS One. 2013 May 22;8(5):e64291
pubmed: 23717584
PLoS One. 2015 Mar 25;10(3):e0117581
pubmed: 25807145
Nature. 2010 Sep 16;467(7313):285-90
pubmed: 20644535
PLoS One. 2012;7(12):e52176
pubmed: 23284924
Stem Cells Transl Med. 2012 May;1(5):430-7
pubmed: 23197822
J Cell Biol. 2016 Oct 24;215(2):187-202
pubmed: 27810911
Circulation. 2012 Sep 11;126(11 Suppl 1):S29-37
pubmed: 22965990

Auteurs

Fumiya Ohashi (F)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Department of Cellular & Gene Therapy Products, Osaka University Graduate School of Pharmaceutical Sciences, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Terumo Corporation, 1500 Inokuchi, Nakai-machi, Ashigarakami-gun, Kanagawa, 259-0151, Japan.

Shigeru Miyagawa (S)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Satoshi Yasuda (S)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.

Takumi Miura (T)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.

Takuya Kuroda (T)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.

Masayoshi Itoh (M)

Preventive Medicine and Diagnosis Innovation Program, RIKEN Center, 1-7-22, Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.

Hideya Kawaji (H)

Preventive Medicine and Diagnosis Innovation Program, RIKEN Center, 1-7-22, Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Preventive Medicine and Applied Genomics Unit, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.

Emiko Ito (E)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Shohei Yoshida (S)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Atsuhiro Saito (A)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Tadashi Sameshima (T)

Terumo Corporation, 1500 Inokuchi, Nakai-machi, Ashigarakami-gun, Kanagawa, 259-0151, Japan.

Jun Kawai (J)

Preventive Medicine and Diagnosis Innovation Program, RIKEN Center, 1-7-22, Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.

Yoshiki Sawa (Y)

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Yoji Sato (Y)

Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan. yoji@nihs.go.jp.
Department of Cellular & Gene Therapy Products, Osaka University Graduate School of Pharmaceutical Sciences, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. yoji@nihs.go.jp.
Department of Quality Assurance Science for Pharmaceuticals, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan. yoji@nihs.go.jp.
Department of Translational Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka, 812-8582, Japan. yoji@nihs.go.jp.
LiSE Laboratory, Kanagawa Institute of Industrial Science and Technology, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-0821, Japan. yoji@nihs.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH